A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates

Cytometry

Volumn 40, Issue 2, 2000, Pages 141-150

  Darden, Janice M ^a   Polonis, Victoria R ^b   DeSouza, Mark S ^b   Chantakulkij, Somsak ^b   Brown, Arthur E ^b   Birx, Deborah L ^c   Pattanapanyasat, Kovit ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Flow cytometry; HIV 1 p24 antigen; Primary isolate neutralization

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL VIABILITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VIRUS ISOLATION;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; ANTIGENS, VIRAL; CELL LINE; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0034212296     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(20000601)40:2<141::AID-CYTO8>3.0.CO;2-F     Document Type: Article

References (52)

1. Albert J, Abrahamson H, Nagy K, Aurelius E, Gaines H, Nystrom G, Fenyo E-M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990;4:107-112.
2. Golding H, D'Souza MP, Bradac J, Mathieson B, Fast P. Neutralization of HIV-1. AIDS Res Hum Retroviruses 1994;10:633-643.
3. Vancott TC, Polonis VH, Loomis LD, Michael NL, Nara PL, Birx DL. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
4. Zolla-Pazner S, Xu S, Burda S, Duliege A, Excler J, Clements-Mann ML. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J Infect Dis 1998;178:1502-1506.
5. McSharry JJ, Costantino R, Robbiano E, Echols R, Stevens R, Lehman JM. Detection and quantitation of human immunodeficiency virus-infected peripheral blood mononuclear cells by flow cytometry. J Clin Microbiol 1990;28:724-733.
6. Burns DPW, Desrosier RC. A cautionary note in the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses 1992;8:1189-1192.
7. Mascola JR, Burke DS. Antigen detection in neutralization assays: high levels of interfering anti-p24 antibodies in some plasma. AIDS Res Hum Retroviruses 1993;9:1173-1174.
8. Poignard P, Klasse PJ, Sattentau QJ. Antibody neutralization of HIV-1. Immunol Today 1996;17:239-246.
9. Ohlsson-Wilhelm BM, Cory JM, Kessler HA, Eyster ME, Rapp F, Landay A. Circulating human immunodeficiency virus (HIV) p24 antigen-positive lymphocytes: a flow cytometric measure of HIV infection. J Infect Dis 1990;162:1018-1024.
10. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159:197-207.
11. Jason J, Larned J. Single-cell cytokine profiles in normal humans: comparison of flow cytometric reagents and stimulation protocols. J Immunol Methods 1997;207:13-22.
12. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Commun Clin Cytometry 1998;34:207-215.
13. Campbell TA, Ware RE, Mason M. Detection of hemoglobin variants in erythrocytes by flow cytometry. Cytometry 1999;35:242-248.
14. Chassagne J, Verrelle P, Dionet C, Clavel F, Barre-Sinoussi F, Chermann J, Montagnier L, Gluckman J, Klatzmann D. A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells. J Immunol 1986;136:1442-1445.
15. Steele-Mortimer OA, Meier-Ewert H, Loser R, Hasmann MJ. Flow cytometric analysis of virus-infected cells and its potential use for screening antiviral agents. J Virol Methods 1990;27:241-252.
16. Laffin J, Lehman JM. Detection of intracellular virus and viral products. Methods Cell Biol 1994;41:543-557.
17. Heynen CA, Holzer TJ. Evaluation of a flow cytometric model for monitoring HIV antigen expression in vitro. J Immunol Methods 1992;152:25-33.
18. Gadol N, Crutcher GJ, Busch MP. Detection of intracellular HIV in lymphocytes by flow cytometry. Cytometry 1994;15:359-370.
19. Cameron PU, Hunter SD, Jolley D, Sonza S, Mijch A, Crowe SM. Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects. Cytometry 1998;33:83-88.
20. Costigliola P, Tumietto F, Ricchi E, Chiodo F. Detection of circulating p24 antigen-positive CD4+ cells during HIV infection by flow cytometry. AIDS 1992;6:1121-1125.
21. Holzer TJ, Heynen CA, Novak RM, Pitrak DL, Dawson GJ. Frequency of cells positive for HIV-1 p24 antigen assessed by flow cytometry. AIDS 1993;7(Suppl 2):S3-S5.
22. Kux A, Bertram S, Hufert FJ, Schmitz H, von Laer D. Antibodies to p24 antigen do not specificially detect HIV-infected lymphocytes in AIDS patients. J Immunol Methods 1996;191:179-186.
23. Cory JM, Ohlsson-Wilhelm BM, Brock EJ, Sheaffer NA, Steck ME, Eyster ME, Rapp F. Detection of human immunodeficiency virus-infected lymphoid cells at low frequency by flow cytometry. J Immunol Methods 1987;105:71-78.
24. Folghera S, Fiorentini S, Martinelli F, Ravizzola G, Gargiulo F, Terlenghi I, De Francesco M, Caruso A, Turano A. Development of a flow cytometric assay for the detection and measurement of neutralizing antibodies against human immunodeficiency virus. Microbiologica 1994;17:21-28.
25. Jason J, Inge L. Increased expression of CD80 and CD86 in in vitro-infected CD3+ cells producing cytoplasmic HIV type 1 p24. AIDS Res Hum Retroviruses 1999;15:173-181.
26. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, Barstad P, Kovacs J, Fauci AS, Folks TM. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989;142:431-438.
27. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989;86:2365-2368.
28. McCutchan FE, Hegerich PA, Brennan TP, Phanuphak P, Singharaj P, Jugsudee A, Berman PW, Gray AM, Fowler AK, Burke DS. Genetic variants in HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8: 1887-1895.
29. Mason CJ, Kitsiripornchai S, Markowitz LE, Chanbancherd P, Supapongse T, Jugsudee A, Sirisopana N, Chuenchitra C, Torugsa K, VanCott TC, Michael RA, Nitayaphan S. Nationwide surveillance of HIV-1 prevalence and subtype in young Thai men. J Acquir Immun Defic Syndr Hum Retrovirol 1998;19:165-173.
30. DAIDS virology manual for HIV laboratories. Division of AIDS, National Institute of Allergy and Infectious Diseases (Publication NIH-97-3828). Washington, DC: U.S. Department of Health and Human Services; 1997.
31. Howell DN, Andreotti PE, Dawson JR, Cresswell P. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 1985;134:971-976.
32. Levy JA. HIV and the pathogenesis of AIDS. Washington, DC: ASM Press; 1994.
33. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-208.
34. Famularo G, Moretti S, Marcellini S, Nucera E, De Simone C. CD8 lymphocytes in HIV infections: helpful and harmful. J Clin Lab Immunol 1997;49:15-32.
35. Clerici M, Balotta C, Galli M. Soluble HIV suppressive factors: more than one Holy Grail? Immunol Today 1996;17:297-298.
36. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
37. Barker E, Bossart KN, Levy JA. Primary CD8+ cells from HIV-infected individuals can suppress productive infection of macrophages independent of β-chemokines. Proc Natl Acad Sci USA 1998;95:1725-1729.
38. Wang L, Klimpel GR, Planas JM, Li H, Cloyd MW. Apoptotic killing of CD4+ T lymphocytes in HIV-1 infected PHA-stimulated PBL cultures is mediated by CD8+ LAK cells. Virology 1998;241:169-180.
39. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, Burke DS. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996;12:1319-1328.
40. Moore JP, Cao YZ, Leu J, Qin JM, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70: 427-444.
41. Kostrikis LG, Cao YZ, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70:445-458.
42. Weber J, Fenyo E-M, Beddows S, Kaleebu P, Bjorndal A. the WHO Network for HIV Isolation and Characterization. Neutralization serotypes of HFV-1 field isolates are not predicted by genetic subtype. J Virol 1996;70:7827-7832.
43. Corrigan GE, Al-Khalili L, Malmsten A, Thorstensson R, Fenyö EM, Källander CFR, Gronowitz JS. Differences in reverse transcriptase activity versus p24 antigen detection in cell culture, when comparing a homogeneous group of HIV type 1 subtype B viruses with a heterogenous group of divergent strains. AIDS Res Hum Retroviruses 1998;14:347-352.
44. Smith T, van Rensburg EJ, Engelbrecht S. Neutralization of HIV-1 subtypes: implications for vaccine formulations. J Med Virol 1998;56: 264-268.
45. Graham BS, Wright PF. Candidate AIDS vaccines. N Engl J Med 1995;333:1331-1339.
46. Van Der Groen G, Nyambi PN, Beirnaert E, Davis D, Fransen K, Heyndrickx L, Ondoa P, Van Der Auwera G. Genetic variation of HIV type 1: relevance of interclade variation to vaccine development. AIDS Res Hum Retroviruses 1998;14(Suppl 3):S211-S221.
47. Brown AE, McNeil JG. HIV vaccine development: a subtype E-specific strategy. Southeast Asian J Trop Med Public Health 1998;29:377-382.
48. Nitayaphan S, Brown AE. Preventive HIV vaccine development in Thailand. AIDS 1998;12(Suppl B):S155-S161.
49. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999;283:357-362.
50. Moore JP, Burton DR. HIV-1 neutralizing antibodies: how full is the bottle? Nat Med 1999;5:142-144.
51. Shibata R, Ingrashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. Neutralizing antibody directed against the HIV-1 envelope glycoprutein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5:204-210.
52. Ingrashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin MA, Shibata R. Human immunodeficiency type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 1999;5:211-216.